0.0900
0.0000
(0.00%)
May 22 - Close
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | - |
| 52 week | 0.01 - 0.12 |
| Open | - |
| Vol / Avg. | 0.00/7,344.00 |
| Mkt cap | 1.40M |
| P/E | 5.08 |
| Div/yield | - |
| EPS | 0.02 |
| Shares | 15.56M |
| Beta | 1.46 |
| Inst. own | 0% |
Events
Apr 15, 2013
Q4 2012 Commonwealth Biotechnologies Inc Earnings Release
|
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | 235.64% | -7.04% |
| Return on average equity | - | -1660.71% |
| Employees | 2 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Commonwealth Biotechnologies, Inc. (CBI) is a specialized life sciences outsourcing business that offered cutting-edge expertise and a complete array of Peptide-based discovery chemistry and biology products and services through Mimotopes Pty Limited (Mimotopes), a wholly-owned subsidiary of CBI. Mimotopes provides research grade peptide synthesis and analysis.
Officers and directors
| Bill Guo | Chairman of the Board | |
| Richard J. Freer Ph.D. | Chief Executive Officer, Chief Operating Officer, Director | |
| Ashley Paul D'Sylva Ph.D. | Director | |
| Maria Song M.D., Ph.D. | Director | |
| James D. Causey | Independent Director | |
| Samuel P. Sears Jr. | Independent Director | |
| Eric V. Tao | Independent Director |